跳至主要内容
临床试验/NCT02729116
NCT02729116进行中(未招募)2 期

Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

Khon Kaen University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
30
试验地点
1
主要终点
Number of patients with clinical cure of acute urinary tract infection

研究概览

简要总结

This study evaluates oral antimicrobial agents for the treatment of non-bacteremic acute urinary tract infection caused by Extended Spectrum Beta Lactamase producing Escherichia coli or Klebsiella pneumoniae in Post-kidney transplantation. Patients are treated with intravenous (IV) antibiotics follow by oral sitafloxacin or IV ertapenem.

详细描述

A prospective randomized controlled trial of patients with a presumptive diagnosis of acute urinary tract infection caused by Extended Spectrum Beta Lactamase-producing Escherichia coli or Klebsiella pneumoniae in Post-kidney transplantation. Intravenous (IV) antibiotic is initially given to all patients. After day 3, patients were randomized to receive either oral sitafloxacin (100 mg twice daily) or intravenous ertapenem. The course of treatment will complete within 14 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Acute urinary infection by definitions
  • Positive urine culture for Extended Spectrum Beta Lactamase E. coli or K. pneumoniae ≥105 colony forming unit/mL
  • Post-kidney transplantation
  • Voluntarily consented to be enrolled in the study

排除标准

  • Positive blood culture
  • Mixed organism of urine culture
  • Immunocompromised conditions other than post-kidney transplantation
  • Pregnancy or lactation
  • Previous urinary tract infections within 4 weeks
  • Contraindicated for fluoroquinolones and carbapenems

研究组 & 干预措施

Sitafloxacin group

Experimental

Sitafloxacin 100 mg oral twice daily

干预措施: Sitafloxacin (Drug)

Ertapenem group

Active Comparator

Ertapenem 1 gm IV every 24 h

干预措施: Ertapenem (Drug)

结局指标

主要结局

Number of patients with clinical cure of acute urinary tract infection

时间窗: 14 days

No symptoms of acute urinary tract infection

次要结局

  • Number of patients with micrological cure of acute urinary tract infection(14 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Atibordee Meesing, MD

Principal Investigator

Khon Kaen University

研究点 (1)

Loading locations...

相似试验

Sitafloxacin and Ertapenem Treatment for Acute... | 临床试验